AML Hub

The AML Hub was pleased to speak with Mark J. Levis, Johns Hopkins University, Baltimore, US. We asked, What is the current clinical landscape of FLT3 inhibitors in the treatment of AML, and what insights have been gained from trials so far? Levis provides an overview of the key FLT3 inhibitors in clinical development for the treatment of FLT3-mutated (FLT3m) AML and discusses ongoing questions, i...

The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What might the future hold for the evolution of FLT3 inhibitors in the treatment of AML? Stein summarizes the approved indications for currently available FLT3 inhibitors and considers potential future directions for their investigation in the treatment of acute myeloid leukemia (AML)...

The AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What are the key ongoing questions in FLT3-mutated AML, and how are ongoing trials addressing these? Craddock begins by highlighting the progress made in the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML) over the past decade with two large randomized clinical tria...

During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Cortes chaired a discussion on the topic, Menin inhibitors in AML: Where are we now, and where are we going? The discussion featured contributions from Charles Craddock, Brian Huntly, and Jeffrey Lancet. This educational resource is independently supported by Johnson & Johnson. All content was developed by SES...

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What side effects are typically observed with menin inhibitor-based regimens, and how do you approach managing them in clinical practice? Roboz provides an overview of the key toxicities associated with menin inhibitor regimens in the treatment of NPM1-mutated (NPM1m) and KMT2A-rearranged (KMT2Ar) acu...

The AML Hub was pleased to speak with Eunice Wang from Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What are the mechanisms and rationale for menin inhibitor combination strategies? Wang summarizes the rationale for menin inhibitor combination strategies for the treatment of NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML), including their potentia...

During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Sierra chaired a discussion on the topic, Treatment decisions in acute myeloid leukemia (AML): Personalizing care with FLT3 inhibitor therapy. The discussion featured contributions from Charles Craddock, Jorge Cortes, Hee-Je Kim, Jeffrey Lancet, Yasushi Miyazaki, Uwe Platzbecker, Roland Walter, and Agnieszka Wierz...

The AML Hub was pleased to speak with Joshua Zeidner, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What key insights are emerging from ongoing trials of menin inhibitor combination strategies in AML? Zeidner provides an overview of currently approved menin inhibitors and discusses combination strategies in development for the treatment of NPM1-mut...

The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between  FLT3 -ITD and -TKD mutations in AML: Implications for clinical practice. The symposium ended with a panel Q&A discussion with live audience participation.  The panelists, Gail J. Roboz, Jorge Sierra, and Jorge Cortes, shared their...

The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3 -ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the symposium by Gail J. Roboz, Weill Cornell Medicine, New York, US, in which she discussed the management of patients with acute myeloid leukemia (AML) with FLT3 -internal tandem duplica...

The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the webinar by Jorge Cortes, Georgia Cancer Center, Augusta, US, discussing treatment options for patients with FLT3-ITD and -TKD mutations. Cortes describes the mechanisms of action of Type I and T...

The AML Hub held a webinar on November 19, 2025, titled, “Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice.” Here, we share one of the presentations, by Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES, discussing the types, prevalence, and clinical significance of FLT3 mutations in acute myeloid leukemia (AML). Sierra pr...

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What are the latest findings from clinical trials of pivekimab sunirine in unfit patients with newly diagnosed acute myeloid leukemia (AML)? In this interview, Roboz discusses key fi...

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How might the phase II PARADIGM trial data impact treatment decisions for newly diagnosed fit adults with acute myeloid leukemia (AML)? In this interview, Fathi discussed key f...

The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the latest data presented on current and emerging treatments for acute myeloid leukemia (AML)? Stein starts by discussing therapies approved for the treatment of IDH1-mutated (IDH1m) AML, including ivosidenib and olutasidenib, and supporting data. He then considers strategies...

The AML Hub was pleased to speak with Emma Searle, The Christie NHS Foundation Trust, Manchester, UK. We asked for her thoughts on the topic “Menin inhibitors in AML: Bridging the gap between trial data and clinical practice.” Searle summarizes the key considerations when using menin inhibitors in the treatment of NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) in cl...

During a meeting of the AML Hub Steering Committee, held on July 22, 2025, Charles Craddock chaired a discussion on the topic: Addressing uncertainty in patient selection for transplant. The discussion featured contributions from Jessica Altman, Courtney DiNardo, Jeffrey Lancet, Roland Walter, and Joshua Zeidner. Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Joshua Zeidner, Associate Professor of Medicine at the University of North Carolina Lineberger Comprehensive Cancer Center in Durham, North Carolina. We asked for his thoughts on the topic “Integrating menin inhibitors into the treatment landscape of AML: Future directions”. Zeidner provides an overview of the latest clinical trial data on menin inhibitors in...

Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the audience addressed by the chair, Charles Craddock, Queen Elizabeth Hospital Birmingham, UK; Gail J. Roboz, Weill Cornell Medicine, New York, US; and Ralph Hills, Connecticut, US....

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Robo...

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Roboz, physician at Weill Cornell Medicine and Know AML Ambassador, and Ralph Hills, Know AML Chair, where they considered the range of genetic mutations in AML and what they mean for treatments, and also...

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a presentation by the chair, Charles Craddock, Queen Elizabeth Hospital Birmingham, UK, discussing mutations and why they matter in AML.  This independent educational activity is supported by Thermo Fisher Scientific. All content...

The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A -mutated acute myeloid leukemia (AML) in remission post intensive chemotherapy? This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders a...

Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment.   Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consensus Classification (ICC) of AML on diagnosis and treatment of high-risk acute myeloid leukemia (HR AML)​?  In this interview, Roboz walks through the changes in the classification criteria for AML...